A potentially severe acute respiratory infection caused by the novel coronavirus severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2).[1] The clinical presentation is generally that of a respiratory infection
with a symptom severity ranging from a mild common cold-like illness, to a severe viral ...
Betacoronavirus/patogenicidad,
Infecciones por Coronavirus/diagnóstico por imagen,
Infecciones por Coronavirus/complicaciones,
Infecciones por Coronavirus/tratamiento farmacológico,
Neumonía Viral/diagnóstico por imagen,
Neumonía Viral/tratamiento farmacológico,
Neumonía Viral/complicaciones,
Pandemias/estadística & datos numéricos,
Brote de los Síntomas,
Grupos de Riesgo,
China/epidemiología,
Neumonía Asociada a la Atención Médica/diagnóstico,
Personal de Salud/organización & administración,
Portador Sano/transmisión,
Transmisión Vertical de Enfermedad Infecciosa/prevención & control
China has managed to control the coronavirus disease (COVID-19) with confinement measurements and treatment strategies, while other countries are struggling to contain the spread. This study discussesthe guidelines related to COVID-19 in China in order to provide important references for other countries
...
Betacoronavirus/efectos de los fármacos,
Neumonía Viral/epidemiología,
Infecciones por Coronavirus/epidemiología,
China/epidemiología,
Pandemias/prevención & control,
Pandemias/estadística & datos numéricos,
Monitoreo Epidemiológico,
Gestión de la Información en Salud/métodos,
Interferones/uso terapéutico,
Lopinavir/uso terapéutico,
Ritonavir/uso terapéutico,
Ribavirina/uso terapéutico,
Cloroquina/uso terapéutico,
Infecciones por Coronavirus/tratamiento farmacológico,
Neumonía Viral/tratamiento farmacológico
The purpose of this guideline is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources....
This clinical practice guideline provides evidence-informed recommendations for infection control, specimen collection, supportive care, pharmacological treatment, and prevention of complications.
The recommendations are directed to all health care staff who deal with patients in emergency departments an...
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice....
The purpose of this guideline is to provide recommendations for managing COVID‑19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection....
The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection, as well their use for chemoprophylaxis. This guidance updates and replaces the recommendations published in A...
This revised guidance is published in two parts. Part II documents the procedures followed in developing this guidance, together with a review of evidence and other new information on the pharmacological agents considered....
Pandemic (H1N1) 2009, the first influenza pandemic of the 21st century, reached all parts of the world within a year, causing epidemics of varying magnitude. During the pandemic period, the World Health Organization (WHO) received reports of over 18 000 laboratory-confirmed deaths due to infection with t...
